<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001083" GROUP_ID="MUSKEL" ID="548799082413040456" MERGED_FROM="" MODIFIED="2010-05-25 15:31:41 -0400" MODIFIED_BY="Michelle Foote" REVIEW_NO="C098-R" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-05-25 15:31:41 -0400" MODIFIED_BY="Michelle Foote">
<TITLE>Cyclosporine for treating rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-05-25 15:31:41 -0400" MODIFIED_BY="Michelle Foote">
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Didier</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Haguenauer</LAST_NAME>
<SUFFIX/>
<POSITION>Rheumatologist</POSITION>
<EMAIL_1>didier.haguenauer@spr.ap-hop-paris.fr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Hopital Ste Perine</ORGANISATION>
<ADDRESS_1>11 rue Chardon Lagache</ADDRESS_1>
<ADDRESS_2/>
<CITY>Paris</CITY>
<ZIP>75016</ZIP>
<REGION/>
<COUNTRY CODE="FR">France</COUNTRY>
<PHONE_1>01-44-96-31-31</PHONE_1>
<PHONE_2/>
<FAX_1>01-44-96-31-79</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13312" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Vivian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Welch</LAST_NAME>
<SUFFIX/>
<POSITION>Research Associate</POSITION>
<EMAIL_1>vivian.welch@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart Street, Room 206</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562-5800 ext: 2921</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health, Department of Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5409" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Joan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Peterson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>jpeterson@ohri.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology Unit</DEPARTMENT>
<ORGANISATION>Ottawa Civic Hospital / Loeb Research Institute</ORGANISATION>
<ADDRESS_1>1053 Carling Avenue</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4E9</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 ext: 8279</PHONE_1>
<PHONE_2/>
<FAX_1>+1 613 761 5351</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-05-27 23:02:50 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="2" YEAR="1998"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="2" YEAR="1998"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="12" YEAR="2000"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="1998"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-27 23:01:28 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-05-27 23:01:28 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. CMSG ID C098-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-27 23:03:14 -0400" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Clinical Epidemiology Unit, University of Ottawa, Ontario</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-15 01:32:00 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-15 01:32:00 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-15 01:29:14 -0400" MODIFIED_BY="[Empty name]">Cyclosporine for treating rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-15 01:32:00 -0400" MODIFIED_BY="[Empty name]">
<P>This review included three trials with a total of 318 patients. A statistically significant decrease in the number of tender and swollen joints was found for patients taking cyclosporine when compared to those taking placebo. Significant improvements in pain and function were also found for those patients taking cyclosporine. More side effects occurred in the cyclosporine group compared to the placebo group.</P>
<P>Cyclosporine has an important clinical benefit in the short-term (up to one year) treatment of patients with progressive rheumatoid arthritis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Rheumatoid arthritis (RA) is an autoimmune disease characterized by an activation of T lymphocyte and an increase in interleukine turnover. In RA, cyclosporine is known to be efficient as a Disease Modifying Anti-Rheumatic Agent (DMARD), especially when other treatments such as injectable gold, D-penicillamine or anti-malarials were not efficacious.<BR/> </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To estimate the short-term (up to one year) effects of cyclosporine for rheumatoid arthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Musculoskeletal Group trials register, and MEDLINE, up to 1997, using the search strategy developed by the Cochrane Collaboration (Dickersin 1994). The search was complemented with bibliography searching of the reference list of the trials retrieved from the electronic search. Key experts in the area were contacted for further published and unpublished articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized clinical trials (RCTs) and controlled clinical trials (CCTs) comparing cyclosporine against placebo in patients with rheumatoid arthritis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers determined the trials to be included based on inclusion and exclusion criteria (GW, MSA). Data were independently abstracted by two reviewers (DH, GW),and checked by a third reviewer (BS) using a pre-developed form for the rheumatoid arthritis sub-group of the Cochrane Musculoskeletal Group. </P>
<P>Methodological quality of the RCTs and CCTs was assessed by two reviewers (BS, DH). Rheumatoid arthritis outcome measures were extracted from the publications for change from baseline endpoints. Sufficient data were obtained to include in the pooled analysis the number of swollen joints, physician global assessment, patient global assessment and erythrocyte sedimentation rate (ESR).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Three trials and 318 patients were included. A statistically significant decrease in the number of tender and swollen joints was observed for cyclosporine when compared to placebo. The standardized mean difference (SMD) for the change in the number of swollen joints was -0.969. Significant improvements in pain and the functional index were also found for cyclosporine. More side effects occurred in the cyclosporine group compared to placebo.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Cyclosporine has an important clinical benefit in the short-term (up to one year) treatment of patients with progressive rheumatoid arthritis.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Rheumatoid arthritis (RA) is an autoimmune disease characterized by an activation of T lymphocyte and an increase in interleukine turnover (<LINK REF="REF-Waalen-1987" TYPE="REFERENCE">Waalen 1987</LINK>). Cyclosporine is a fungal peptide with immunosuppressive properties, inhibiting T lymphocytes and the production of cytokines (<LINK REF="REF-Hess-1982" TYPE="REFERENCE">Hess 1982</LINK>) and has been used as an antimetic agent to prevent graft rejection. As for RA, cyclosporine is known to be efficient as a Disease Modifying Anti-Rheumatic Agent (DMARD), especially when other treatments such as injectable gold, D-penicillamine or anti-malarials were not efficacious.</P>
<P>The first trials used cyclosporine with high doses and doses had to be decreased because of adverse effects, such as hypertension or increasing creatinemiea. Subsequent study designs started with low doses, and doses were increased when no adverse effects were seen with respect to blood counts or renal function. Preliminary open uncontrolled studies have been constructed using high doses of cyclosporine (10mg/kg/day) (<LINK REF="REF-Dougados-1993" TYPE="REFERENCE">Dougados 1993</LINK>). It was clear that the effect of cyclosporine and the side effects were modulated by the doses of the drug. A few placebo controlled studies used initial low doses of the drug (2.5-5 mg/kg/day) to minimize the side effects (<LINK REF="STD-Tugwell-1990" TYPE="STUDY">Tugwell 1990</LINK>, <LINK REF="STD-Dougados-1988" TYPE="STUDY">Dougados 1988</LINK>, <LINK REF="STD-Forre-1994" TYPE="STUDY">Forre 1994</LINK>). The average dose of cyclosporine ranges from 3.7 to 4.4 mg/kg/day.</P>
<P>The estimate of the magnitude of the clinical benefits and side effects found with cyclosporine in RA varies considerably across studies. Data obtained with these studies suggest that cyclosporine is more than a symptomatic treatment of RA but can be also considered as a DMARD, in terms of the effect of this drug on the evolution of the disease (<LINK REF="REF-Dougados-1993" TYPE="REFERENCE">Dougados 1993</LINK>). Data of previous studies agree that cyclosporine is effective and probably of benefit in patients with active diseases and refractory RA (<LINK REF="REF-Intl-consensus-1993" TYPE="REFERENCE">Intl consensus 1993</LINK>).</P>
<P>Further trials have studied the efficacy of cyclosporine versus other DMARDs, including azathioprine (<LINK REF="REF-Kruger-1992" TYPE="REFERENCE">Kruger 1992</LINK>) and D-penicillamine (<LINK REF="REF-Van-Rijthoven-1991" TYPE="REFERENCE">Van Rijthoven 1991</LINK>) or the efficacy of cyclosporine combined with other treatment, such as vitamin D (<LINK REF="REF-Gepner-1989" TYPE="REFERENCE">Gepner 1989</LINK>) and Bromocriptine (<LINK REF="STD-Dougados-1988" TYPE="STUDY">Dougados 1988</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To conduct a systematic review of the literature on the short term efficacy and toxicity of cyclosporine.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomized clinical trials (RCTs) and controlled clinical trials (CCTs) published in English, with a minimum duration of study of 16 weeks.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a diagnosis of rheumatoid arthritis according to the American Rheumatism Association (ARA) criteria for classic or definite RA (specific details of the activity of RA stated in the publications).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intervention group : cyclosporine for at least 16 weeks.<BR/>Control group : placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>All the outcome measures in OMERACT (<LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>) were included for the planned analysis, although only some were consistently measured. </P>
<P>OMERACT measures for efficacy include :<BR/>a) Number of tender joints<BR/>b) Number of swollen joints<BR/>c) Acute phase reactants<BR/>d) Pain<BR/>e) Functional status<BR/>f) Physician global assessment<BR/>g) Patient global assessment<BR/>h) Radiological damage</P>
<P>Toxicity was evaluated using withdrawals and dropouts (total and organ-specific).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>An electronic literature search was conducted using MEDLINE, from 1966 to 1997, using the search strategy developed by the Cochrane Collaboration (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). The search was complemented with bibliography searching of the reference list of the trials retrieved from the electronic search. Key experts in the area were contacted for further published and unpublished articles.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data extracted from the publications included study characteristics and outcome measures of efficacy and toxicity. The toxicity results were generally reported as overall results at the end of the trial, and were therefore pooled for different trial follow-ups. Toxicity was analyzed using a pooled odds ratio for total withdrawals, and dropouts and withdrawals for specific reasons.</P>
<P>Heterogeneity was estimated using a chi-square test. Fixed effects models were carried out throughout, except when heterogeneity existed, in which case, a random effects model was used.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Three RCTs met the criteria for inclusion (<LINK REF="STD-Tugwell-1990" TYPE="STUDY">Tugwell 1990</LINK>, <LINK REF="STD-Dougados-1988" TYPE="STUDY">Dougados 1988</LINK>, <LINK REF="STD-Forre-1994" TYPE="STUDY">Forre 1994</LINK>). One study was excluded (<LINK REF="STD-Van-Rijthoven-1986" TYPE="STUDY">Van Rijthoven 1986</LINK>) because of the high dose of cyclosporine (10 mg/kg/day) used. Tugwell did not use the Ritchie index but the number of joints (0 to 68 for tender and 0 to 66 for swollen joints). Forre used a pain score from 0 to 4 whereas Tugwell and Dougados used a 10 cm visual analogue scale (VAS) for pain. Duration of morning stiffness was measured in hours by Tugwell and in minutes in the other studies. The Lee functional index was not used by Tugwell. Different scales were used to assess patient or physician overall assessment. These assessments were transformed to a 7 point scale from -3 to 3.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the studies was assessed independently by 2 of the reviewers (BS, DH) using a validated and published quality scale (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). This scale includes an assessment of randomization, double-blinding procedures and description of withdrawals. The possible range of scores is 0 (worst) to 5 (best). Two of the studies had a score of 4 and the other a score of 5. The kappa for agreement between observers on the quality scores was 1.0.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>There was a statistically significant reduction in the number of tender (SMD=-0.60, 95% CI: -0.934, -0.266) and swollen (SMD=-0.623, 95% CI: -0.851, -0.395) joints using cyclosporine compared to placebo. Statistically significant differences favouring cyclosporine were also observed for pain, Lee's functional index and Ritchie joint score.</P>
<P>The data available on side effects indicated more side effects with cyclosporine, namely: headache (OR=3.4, 95% CI: 1.1, 10.4), tremor (OR=5.3, 95% CI: 2.8, 9.9), dyspepsis (OR=2.0, 95% CI: 1.1, 3.6), nausea (OR=2.2, 95% CI: 1.2, 3.8), paraesthesia (OR = 2.3, 95% CI: 1.1, 4.9) and gum hyperplasia (OR = 8.0, 95% CI: 2.1, 30.2).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Heterogeneity was not an important factor in the evaluation of the RCTs and the results are presented are based on a fixed effects approach. The purpose of this systematic review was to evaluate the efficacy and toxicity of cyclosporine treatment of patients with RA. The studies pooled all directly addressed the objective and used similar criteria for RA, the disease of interest. Study selection bias was minimized by selecting only randomized trials. Although some of the major outcome measures in the trials were sufficiently homogeneous to allow pooling, there was some lack of standardization of the outcome measurements and even omission of some in some studies. These studies were all conducted before the establishment of the OMERACT and the American College of Rheumatology (ACR) core set of measures for RA. Many of the measures evaluated are considered nowadays of doubtful value (eg. grip strength). There was some degree of consistency in the reporting of results, with the endpoints presented as simple change from baseline.</P>
<P>The pooled estimate of clinical benefit from cyclosporine in the present meta-analysis provides an estimate of benefit that makes appropriate adjustments for the different sample sizes and degree of precision across the studies. It also takes into account the use of different scoring techniques by standardizing the weighted differences (e.g. different number of possible swollen joints measured in each study). The variables for which there was sufficient data for pooling (number of swollen joints, VAS Pain and Lee's functional index) all showed a statistically significant benefit when compared to placebo. </P>
<P>Toxicity was increased in the cyclosporine group. The following side effects were 2 to 5 fold more likely to occur with cyclosporine then placebo: headaches, tremor, dyspepsis, nausea and paresthesia. Cohort studies may be more appropriate to evaluate the incidence of these disorders. </P>
<P>Cyclosporine has an important clinical benefit in the short term for patients with progressive rheumatic disease.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Positive effects using cyclosporine were obtained in trials involving patients with very severe refractory active RA. Clinically, restriction of the drug to such individuals is suggested by its potentially irreversible toxicity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Since there are additional specific issues particularly relevant to slow acting antirheumatic drugs, it might be useful to consider establishing supplementary guidelines or criteria for the standardization of reporting for clinical trials of antirheumatic drugs, following the guidelines from CONSORT (Bedd 1996); this would avoid the need to obtain additional data and analyses from the original investigators (which is often hard to obtain after the study is published). Specific issues for RA include:</P>
<P>(1) Standardization of timing: there is considerable variation in the duration of trials of many of the slow acting anti-rheumatic drugs which makes it difficult to compare them; thus the timing of assessments should be at regular intervals, preferably standardized, so that studies of longer duration can be compared with shorter ones using data at the same points in time. The clinical heterogeneity in the follow-up duration of the studies included in this review only allowed us to pool results for the first 6 months of treatment.<BR/>(2) Comparability of groups: the description of the demographic and clinical characteristics of the patients is important, to allow for meaningful pooling of results and generalizability<BR/>(3) Details of the inclusion and exclusion criteria are also needed for deciding on the generalizability of the results. For example, there are frequently age restrictions because of the regulatory agencies' concerns about toxicity in the elderly, yet this age group poses major therapeutic challenges and good quality data are needed for informed decisions.<BR/>(4) Different drug studies use different outcomes and different methods of measuring them, making it difficult or impossible to compare or combine the results. These issues will hopefully be resolved by applying the criteria established by OMERACT and the ACR in relation to the evaluation of patients with RA in clinical trials.<BR/>(5) Some studies publish only the end-of-treatment results while others publish the difference between beginning and end of treatment; some publish their statistics as medians while others publish just means. For valid meta-analysis (or simple comparisons by clinicians reading the articles) manuscripts should provide standardized data on each endpoint, perhaps a minimum of the following: means and medians of each one at baseline and at end of treatment, plus their variance.<BR/>(6) Although the reporting of means or medians is the traditional method of reporting the magnitude of benefit, clinical significance can be usefully complemented by reporting the proportion of patients achieving a predetermined degree of improvement. This provides useful information to the clinician on the probability of a major improvement. Several sets of criteria are available (Paulus, ACR and Eular). This information on the proportion of patients achieving a specified level of improvement can be combined across studies. The proportion of patients improving or developing adverse reactions, rather than means, is also needed for developing decision analysis algorithms, another important application of a pooled estimate.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank the Cochrane Musculoskeletal Group for the valuable review of this document. Many thanks to Dr. Ann Cranney for editorial review of this manuscript.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-1988" NAME="Dougados 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis : a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1998; 47: 127-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Awada H, Amor B</AU>
<TI>Cyclosporin in rheumatoid arthritis : a double blind, placebo controlled study in 52 patients</TI>
<SO>Ann Rheum Dis</SO>
<YR>1998</YR>
<VL>47</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Forre-1994" NAME="Forre 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Forre O and the Norvegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Arthritis Rheum 1994; 37: 1506-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Forre O and the Norvegian Arthritis Study Group</AU>
<TI>Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine</TI>
<SO>Arthritis Rheum</SO>
<YR>1994</YR>
<VL>37</VL>
<PG>1506-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tugwell-1990" NAME="Tugwell 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Bombardier C, Gent M, et al</AU>
<TI>Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>1051-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Rijthoven-1986" NAME="Van Rijthoven 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Van Rijthoven A, Dijkmans BA, Goei The H et al. Cyclosporin treatment for rheumathoid arthritis : a placebo controlled, double-blind, multicenter study. Ann Rheum Dis 1986; 45: 726-31.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Rijthoven A, Dijkmans BA, Goei The H et al</AU>
<TI>Cyclosporin treatment for rheumathoid arthritis : a placebo controlled, double-blind, multicenter study</TI>
<SO>Ann Rheum Dis</SO>
<YR>1986</YR>
<VL>45</VL>
<PG>726-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K</AU>
<TI>, Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-1988" NAME="Dougados 1988" NOTES="&lt;p&gt;Dougados M, Duchene l, Amor B. Bromocriptin and cyclosporine A combination therapy in rheumatoid arthritis. Arthritis Rheum 1988; 31: 1331-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Duchene l, Amor B</AU>
<TI>Bromocriptin and cyclosporine A combination therapy in rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>1331-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dougados-1993" NAME="Dougados 1993" NOTES="&lt;p&gt;Dougados M, Torley H. Efficacy of cyclosporin A in rheumatoid arthritis : worldwide experience. Br J Rheum 1993; 32(suppl 1): 57-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Torley H</AU>
<TI>Efficacy of cyclosporin A in rheumatoid arthritis : worldwide experience</TI>
<SO>Br J Rheum</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>suppl 1</NO>
<PG>57-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gepner-1989" NAME="Gepner 1989" NOTES="&lt;p&gt;Gepner , Amor B, Fournier C. 1.25. hydroxy vitamin D3 potentiates the in vitro inhibitory effects of cyclosporine A on T cells from rheumatoid arthritis patients. Arthritis Rheum 1989; 22: 31-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gepner , Amor B, Fournier C</AU>
<TI>1.25. hydroxy vitamin D3 potentiates the in vitro inhibitory effects of cyclosporine A on T cells from rheumatoid arthritis patients</TI>
<SO>Arthritis Rheum</SO>
<YR>1989</YR>
<VL>22</VL>
<PG>31-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hess-1982" NAME="Hess 1982" NOTES="&lt;p&gt;Hess A, Turschka P, Pu Z et al. Effects of cyclosporine A on human lymphocyte response in vitro. J Immunol 1982; 128: 360-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Hess A, Turschka P, Pu Z et al</AU>
<TI>Effects of cyclosporine A on human lymphocyte response in vitro</TI>
<SO>J Immunol</SO>
<YR>1982</YR>
<VL>128</VL>
<PG>360-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Intl-consensus-1993" NAME="Intl consensus 1993" NOTES="&lt;p&gt;An International consensus report : the use of cyclosporin A in rheumatoid arthritis. Br J Rheum 1993; 32 (suppl 1): 1-3.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>An International consensus report : the use of cyclosporin A in rheumatoid arthritis</AU>
<SO>Br J Rheum</SO>
<YR>1993</YR>
<VL>32</VL>
<NO>suppl 1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" NOTES="&lt;p&gt;Jadad A, Moore A, Carrol D et al. Assessing the quality of reports of randomized trials: is blinding necessary? Control Clin Trial 1996; 17 : 1-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D et al</AU>
<TI>Assessing the quality of reports of randomized trials: is blinding necessary?</TI>
<SO>Control Clin Trial</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kruger-1992" NAME="Kruger 1992" NOTES="&lt;p&gt;Kruger K, Schattenkirchner M. Cyclosporine versus azathioprine in the treatment of rheumatoid arthritis ; results of a controlled double blind multicenter study(abstract). J Autoimmun 1992; 5, xix.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kruger K, Schattenkirchner M</AU>
<TI>Cyclosporine versus azathioprine in the treatment of rheumatoid arthritis ; results of a controlled double blind multicenter study(abstract)</TI>
<SO>J Autoimmun</SO>
<YR>1992</YR>
<VL>5, xix</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" NAME="OMERACT 1993" NOTES="&lt;p&gt;OMERACT. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. J Rheumatol 1993 ; 20 : 526-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials</TI>
<SO>J Rheumatol</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Rijthoven-1991" NAME="Van Rijthoven 1991" NOTES="&lt;p&gt;Van Rijthoven AW, Dijkmans BA, Goei The HS, et al. Comparison of cyclosporine and D penicillamine for rheumatoid arthritis : a randomized double blind multicenter study. J Rheumatol 1991; 18: 815-20.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Van Rijthoven AW, Dijkmans BA, Goei The HS, et al</AU>
<TI>Comparison of cyclosporine and D penicillamine for rheumatoid arthritis : a randomized double blind multicenter study</TI>
<SO>J Rheumatol</SO>
<YR>1991</YR>
<VL>18</VL>
<PG>815-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waalen-1987" NAME="Waalen 1987" NOTES="&lt;p&gt;Waalen K, Forre O, Linker M et al. Evidence of an activated T cell system with augmented turn over of interleukin 2 in rheumatoid arthritis. Scand J Immunol 1987; 25: 367-73&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Waalen K, Forre O, Linker M et al</AU>
<TI>Evidence of an activated T cell system with augmented turn over of interleukin 2 in rheumatoid arthritis</TI>
<SO>Scand J Immunol</SO>
<YR>1987</YR>
<VL>25</VL>
<PG>367-73</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Dougados-1988">
<CHAR_METHODS>
<P>Randomized<BR/>Double blind<BR/>Placebo controlled<BR/>Sample size at entry : cyclo : 26; placebo : 26.<BR/>Study duration : 16 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA (ARA definite or classic)<BR/>Setting : clinic outpatients<BR/>Mean age (yrs) : 57.5<BR/>Sex : F/M : cyclo ; 23/3; placebo : 24/2<BR/>Disease duration : cyclo : 8.0; placebo : 15.0</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cyclosporine twice daily at 5mg/kg/day or 2.5 mg/kg/day for those concurrently taking cimetidine.<BR/>Dose reduced by half if renal toxicity appeared (defined as &gt;50% increase in plasma creatinine level over baseline), halved again if toxicity persists 1 wk later and discontinued if toxicity persists 1 wk after 2nd reduction.<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain<BR/>Ritchie index<BR/>Morning stiffness duration<BR/>Swollen joint<BR/>PIP circumference<BR/>Grip strengh<BR/>Lee functional index<BR/>Patient global assessment<BR/>ESR<BR/>CRP<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score : 4<BR/>Concealment of allocation : B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Forre-1994">
<CHAR_METHODS>
<P>Randomized<BR/>Double blind<BR/>Placebo controlled<BR/>Sample size at entry : cyclo : 61; placebo : 61.<BR/>Study duration : 48 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA<BR/>Setting : multicenter study (6)<BR/>Mean age (yrs) : cyclo :52.4; placebo 50.3<BR/>Sex % F : cyclo : 68; placebo : 67<BR/>Disease duration : cyclo : 8.8; placebo : 8.1<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cyclosporine twice daily, 5mg/kg/day;<BR/>Dose reduced by half if toxicity appeared (defined as serum creatinine &gt;50% above baseline or &gt; 150 umol/L, increase in bilirubin or transaminse levels twice upper limit of normal or increase in serum potassium above upper limit), halved again if toxicity persisted 2 wks later and discontinued if toxicity persisted 2 wks after second reduction.<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain<BR/>Ritchie index<BR/>Morning stiffness duration<BR/>Swollen joint<BR/>PIP circumference<BR/>Grip strengh<BR/>Lee functional index<BR/>Patient globall assessment<BR/>Physician global assessment<BR/>ESR<BR/>CRP<BR/>Larsen score<BR/>Number of erosions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score : 5<BR/>Concealment of allocation : B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tugwell-1990">
<CHAR_METHODS>
<P>Randomized<BR/>Double blind<BR/>Placebo controlled<BR/>Sample size at entry : cyclo : 72; placebo : 72.<BR/>Study duration : 24 weeks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA (ARA definite or classic)<BR/>Setting : clinic outpatients; multicenter study<BR/>Mean age (yrs) : cyclo : 54.4; placebo : 55.2<BR/>Sex % : cyclo ; 72; placebo : 69<BR/>Disease duration : cyclo : 10.9; placebo : 11.1</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Cyclosporine twice daily, dose 2.5 mg/kg/day;<BR/>Dose increased weekly by 25% until serum trough levels of cyclosporine of 75-150 ng/mL achieved unless prevented by &gt;50% in serum creatinine;<BR/>Dose reduced by 25-50% if <BR/> a) Toxicity found (measured by serum creatinine increase to baseline value + 75% or if &gt;150 micromol/L)<BR/> b) Trough serum cyclosporine levels &gt;150 ng/mL<BR/> c) Serum AST, alkaline phosphatase, serum potassium, blood pressure abnormal<BR/>Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain<BR/>Morning stiffness duration<BR/>Swollen joint<BR/>Grip strengh<BR/>ESR<BR/>Patient global assessment<BR/>Physician global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score : 4<BR/>Concealment of allocation : B</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Van-Rijthoven-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was excluded because of the high dose of cyclosporine (10 mg/kg/day).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dougados-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Forre-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tugwell-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Cyclosporine vs placebo - Efficacy</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.7569988558041523" CI_START="-12.64300114419585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.200000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.976827152288865E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="99.99999999999999" Z="3.617308245401613">
<NAME>Change in number of tender joints</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.7569988558041523" CI_START="-12.64300114419585" EFFECT_SIZE="-8.200000000000001" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-1.2" ORDER="4" SD_1="14.42" SD_2="12.73" SE="2.266878972900357" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.9091408683042226" CI_END="-2.095077631988694" CI_START="-4.2866077492019405" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.1908426905953173" ESTIMABLE="YES" I2="31.25118065644491" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.23350069544800112" P_Q="1.0" P_Z="1.1473510955736502E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="5.707370119879733">
<NAME>Change in number of swollen joints</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.2879164701211634" CI_START="-8.592083529878835" EFFECT_SIZE="-5.4399999999999995" ESTIMABLE="YES" MEAN_1="-3.36" MEAN_2="2.08" ORDER="4" SD_1="4.63" SD_2="6.22" SE="1.6082354342947465" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="12.08479979278508"/>
<CONT_DATA CI_END="-0.49312502846662576" CI_START="-4.106874971533375" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-0.9" ORDER="4" SD_1="5.94" SD_2="5.09" SE="0.9218919254566786" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="36.77720249702834"/>
<CONT_DATA CI_END="-1.76769369708827" CI_START="-4.83230630291173" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-0.3" ORDER="5" SD_1="4.69" SD_2="3.91" SE="0.7818032958760298" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="51.137997710186575"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="35.6222095777116" CI_END="0.4108129724878236" CI_START="-0.24993130719659212" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08044083264561575" ESTIMABLE="YES" I2="97.19276257184875" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="2.395479148376012E-9" P_Q="1.0" P_Z="0.6332034416340514" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="0.4772228522269545">
<NAME>Change in patient overall assessment</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3609785187842687" CI_START="-1.239021481215731" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.9" ORDER="4" SD_1="0.85" SD_2="1.7" SE="0.22399466759526018" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="56.62853041154603"/>
<CONT_DATA CI_END="1.7316506130728084" CI_START="0.7283493869271915" EFFECT_SIZE="1.23" ESTIMABLE="YES" MEAN_1="2.02" MEAN_2="0.79" ORDER="5" SD_1="1.56" SD_2="1.25" SE="0.2559488934642496" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="43.37146958845397"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.17321124075243" CI_END="0.6909716866992319" CI_START="-0.018674797643256413" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.33614844452798776" ESTIMABLE="YES" I2="96.31990495661303" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.8602067652917498E-7" P_Q="1.0" P_Z="0.0633383908768283" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="1.8568085920821633">
<NAME>Change in physician overall assessment</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.24467687104698443" CI_START="-1.3553231289530152" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.9" ORDER="4" SD_1="1.7" SD_2="1.7" SE="0.2833333333333333" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="40.82560184750064"/>
<CONT_DATA CI_END="1.5812592995324493" CI_START="0.658740700467551" EFFECT_SIZE="1.12" ESTIMABLE="YES" MEAN_1="1.79" MEAN_2="0.67" ORDER="5" SD_1="1.48" SD_2="1.09" SE="0.2353407017530953" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="59.17439815249936"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1211252130548974" CI_END="4.4270946591230995" CI_START="-5.494975093794922" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5339402173359109" ESTIMABLE="YES" I2="3.880818768444807" I2_Q="3.7515995629412227" ID="CMP-001.05" NO="5" P_CHI2="0.37332473775090425" P_Q="0.3080595421507635" P_Z="0.8329304891330056" Q="1.0389783055708501" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="216" TOTAL_2="218" UNITS="" WEIGHT="200.00000000000003" Z="0.2109446157779941">
<NAME>Acute phase reactants</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0821469074840473" CI_END="4.851142999653867" CI_START="-5.173852219109966" DF="2" EFFECT_SIZE="-0.1613546097280496" ESTIMABLE="YES" I2="3.945298345125375" ID="CMP-001.05.01" NO="1" P_CHI2="0.35307562886736665" P_Z="0.9496931295655017" STUDIES="3" TAU2="0.0" TOTAL_1="155" TOTAL_2="157" WEIGHT="100.00000000000003" Z="0.06309214456572872">
<NAME>Change in ESR</NAME>
<CONT_DATA CI_END="7.783599525433155" CI_START="-4.183599525433156" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-3.4" ORDER="4" SD_1="13.58" SD_2="22.06" SE="3.052912998723969" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="70.1751450328505"/>
<CONT_DATA CI_END="10.47058727395605" CI_START="-13.47058727395605" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.0" ORDER="5" SD_1="36.71" SD_2="30.46" SE="6.107554714463386" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="17.53385627768895"/>
<CONT_DATA CI_END="4.847516035864066" CI_START="-23.747516035864066" EFFECT_SIZE="-9.45" ESTIMABLE="YES" MEAN_1="-8.91" MEAN_2="0.54" ORDER="17050" SD_1="28.42" SD_2="19.9" SE="7.294785082093878" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="12.290998689460572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.310073439219643" CI_START="-53.11007343921964" DF="0" EFFECT_SIZE="-18.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="1.0" P_Z="0.29881049913751345" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="1.0389876408267196">
<NAME>Change in CRP</NAME>
<CONT_DATA CI_END="16.310073439219643" CI_START="-53.11007343921964" EFFECT_SIZE="-18.4" ESTIMABLE="YES" MEAN_1="-13.4" MEAN_2="5.0" ORDER="5" SD_1="62.48" SD_2="123.4" SE="17.709546559532864" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.885364806866952" CI_END="-0.07110849698678579" CI_START="-0.3185567390647164" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19483261802575108" ESTIMABLE="YES" I2="65.34233738416457" I2_Q="65.34233738416457" ID="CMP-001.06" NO="6" P_CHI2="0.08938789064591635" P_Q="0.08938789064591635" P_Z="0.002025807292920286" Q="2.885364806866952" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="46" UNITS="" WEIGHT="200.0" Z="3.08642252729246">
<NAME>Radiologic evaluation</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.055097774153034754" CI_START="-0.3049022258469653" DF="0" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.004734595411875898" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0" Z="2.8245574874659574">
<NAME>Change in larsen score</NAME>
<CONT_DATA CI_END="-0.055097774153034754" CI_START="-0.3049022258469653" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.17" ORDER="5" SD_1="0.24" SD_2="0.24" SE="0.06372679642696401" STUDY_ID="STD-Forre-1994" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0670597424933671" CI_START="-1.8729402575066327" DF="0" EFFECT_SIZE="-0.97" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.02" NO="2" P_CHI2="1.0" P_Z="0.03524546214153546" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0" Z="2.1055269705813147">
<NAME>Change in erosion score</NAME>
<CONT_DATA CI_END="-0.0670597424933671" CI_START="-1.8729402575066327" EFFECT_SIZE="-0.97" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="1.03" ORDER="5" SD_1="1.82" SD_2="1.68" SE="0.4606922701788963" STUDY_ID="STD-Forre-1994" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.1903206880641889" CI_END="-2.328649989108184" CI_START="-5.158645770133627" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7436478796209056" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.909227193710328" P_Q="0.8305240018806977" P_Z="2.154822907117552E-7" Q="0.04580873895929766" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="200.0" Z="5.185460037822401">
<NAME>Index scores</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.14451194910489124" CI_END="-2.3271831451407166" CI_START="-5.157296428275375" DF="1" EFFECT_SIZE="-3.7422397867080455" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="0.7038362283385685" P_Z="2.1800048802319916E-7" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="85" WEIGHT="100.0" Z="5.183294426530302">
<NAME>Change in Lee functional index</NAME>
<CONT_DATA CI_END="-1.38296786900349" CI_START="-5.51703213099651" EFFECT_SIZE="-3.45" ESTIMABLE="YES" MEAN_1="-3.91" MEAN_2="-0.46" ORDER="4" SD_1="3.01" SD_2="4.1" SE="1.0546276091300635" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="46.86549332580997"/>
<CONT_DATA CI_END="-2.0587319909685964" CI_START="-5.941268009031404" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="1.8" ORDER="5" SD_1="5.47" SD_2="5.47" SE="0.9904610617051527" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="53.13450667419003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="134.5831674168705" CI_START="-175.9831674168705" DF="0" EFFECT_SIZE="-20.7" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.03" NO="3" P_CHI2="1.0" P_Z="0.7938822078403558" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="0.2612727132945597">
<NAME>Change in problem elicitation technique (PET)</NAME>
<CONT_DATA CI_END="134.5831674168705" CI_START="-175.9831674168705" EFFECT_SIZE="-20.7" ESTIMABLE="YES" MEAN_1="-44.9" MEAN_2="-24.2" ORDER="4" SD_1="450.57" SD_2="498.93" SE="79.22756164997128" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1018941681471146" CI_END="-18.250639964245032" CI_START="-90.37489023494652" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-54.31276509959578" ESTIMABLE="YES" I2="4.847730665570927" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.3496066604565822" P_Q="1.0" P_Z="0.0031584571913137794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.00000000000001" Z="2.9518799321019658">
<NAME>Change in duration of morning stiffness</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-21.452892779303923" CI_START="-171.30710722069608" EFFECT_SIZE="-96.38" ESTIMABLE="YES" MEAN_1="-108.05" MEAN_2="-11.67" ORDER="4" SD_1="112.22" SD_2="146.07" SE="38.22881839243554" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="23.164594417116458"/>
<CONT_DATA CI_END="19.810976840282066" CI_START="-163.81097684028208" EFFECT_SIZE="-72.0" ESTIMABLE="YES" MEAN_1="-102.0" MEAN_2="-30.0" ORDER="4" SD_1="254.4" SD_2="305.4" SE="46.843195877309654" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="15.42813447946983"/>
<CONT_DATA CI_END="12.019449269533887" CI_START="-80.01944926953388" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="-46.2" MEAN_2="-12.2" ORDER="5" SD_1="131.99" SD_2="127.31" SE="23.479742297577623" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="61.40727110341372"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.563845078242165" CI_END="27.596219982424884" CI_START="5.1880380922670515" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="16.392129037345967" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.45752570379421265" P_Q="1.0" P_Z="0.004136994259639956" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="2.8675224701958215">
<NAME>Change in Grip Strength</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.90633876801876" CI_START="6.693661231981238" EFFECT_SIZE="20.3" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="1.8" ORDER="4" SD_1="44.12" SD_2="39.03" SE="6.942137138918789" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="67.80640062775552"/>
<CONT_DATA CI_END="40.916078209697325" CI_START="-11.316078209697324" EFFECT_SIZE="14.8" ESTIMABLE="YES" MEAN_1="16.68" MEAN_2="1.88" ORDER="4" SD_1="48.29" SD_2="41.44" SE="13.324774544684297" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="18.40506390656328"/>
<CONT_DATA CI_END="29.472934857669365" CI_START="-30.872934857669364" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.3" ORDER="5" SD_1="111.69" SD_2="44.52" SE="15.394637399293876" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="13.788535465681196"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.095562758606433" CI_END="-2.440970815211618" CI_START="-9.889292275154059" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.165131545182838" ESTIMABLE="YES" I2="8.722709662748096" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.295242441847977" P_Q="1.0" P_Z="0.001176130632884556" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="3.2446064132692567">
<NAME>Change in PIP circumference</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.1924454971885403" CI_START="-16.92755450281146" EFFECT_SIZE="-9.56" ESTIMABLE="YES" MEAN_1="-3.77" MEAN_2="5.79" ORDER="4" SD_1="11.75" SD_2="13.73" SE="3.759025451960235" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="25.55113037681663"/>
<CONT_DATA CI_END="-0.6838218462454231" CI_START="-9.316178153754578" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="0.0" ORDER="17066" SD_1="10.93" SD_2="13.28" SE="2.202172176529793" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="74.44886962318337"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.018429237770830897" CI_END="-2.017447699111642" CI_START="-8.195116887311473" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.1062822932115575" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.11" NO="11" P_CHI2="0.8920155035142348" P_Q="1.0" P_Z="0.0011948827249374132" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="3.240098841390247">
<NAME>Change in Ritchie Joint Score</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.26802536322654635" CI_START="-9.471974636773453" EFFECT_SIZE="-4.87" ESTIMABLE="YES" MEAN_1="-4.91" MEAN_2="-0.04" ORDER="4" SD_1="7.81" SD_2="8.11" SE="2.3479893881077625" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="45.050629485684325"/>
<CONT_DATA CI_END="-1.1330979495085156" CI_START="-9.466902050491486" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-2.4" ORDER="5" SD_1="12.5" SD_2="10.93" SE="2.1260094998476893" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="54.94937051431568"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.636662281322096" CI_END="0.49502690988384934" CI_START="-0.03267722978814114" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2311748400478541" ESTIMABLE="YES" I2="87.20954661539893" I2_Q="93.59776600319196" ID="CMP-001.12" NO="12" P_CHI2="4.022937486547473E-4" P_Q="7.745039486461991E-5" P_Z="0.0859373840942885" Q="15.619547809382968" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="200.0" Z="1.7172287521080867">
<NAME>Pain scores</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.017114471939126966" CI_END="-0.5731549980090026" CI_START="-2.317901123737127" DF="1" EFFECT_SIZE="-1.445528060873065" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="0.8959158934704388" P_Z="0.0011635267406464157" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="96" WEIGHT="100.0" Z="3.247673568291633">
<NAME>Change in pain (10 cm VAS)</NAME>
<CONT_DATA CI_END="-0.10370639769457801" CI_START="-2.936293602305422" EFFECT_SIZE="-1.52" ESTIMABLE="YES" MEAN_1="-1.84" MEAN_2="-0.32" ORDER="4" SD_1="2.77" SD_2="2.04" SE="0.7226120548525203" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="37.94005072755414"/>
<CONT_DATA CI_END="-0.2926203487348691" CI_START="-2.507379651265131" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.9" ORDER="5" SD_1="3.39" SD_2="3.39" SE="0.5650000000000001" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="62.059949272445856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6768170104286098" CI_START="0.12318298957139034" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.02" NO="2" P_CHI2="1.0" P_Z="0.004623704242544799" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="2.8321438505608363">
<NAME>Change in pain (1-max pain to 4-no pain, Likert scale)</NAME>
<CONT_DATA CI_END="0.6768170104286098" CI_START="0.12318298957139034" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.1" ORDER="4" SD_1="0.78" SD_2="0.78" SE="0.1412357638263289" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Cyclosporine vs placebo - Toxicity</NAME>
<DICH_OUTCOME CHI2="0.07501279169215946" CI_END="12.119357741072655" CI_START="4.382681581844183" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.288023460141978" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.0834796052346545" LOG_CI_START="0.6417399186869436" LOG_EFFECT_SIZE="0.862609761960799" METHOD="PETO" NO="1" P_CHI2="0.9631882578967655" P_Q="1.0" P_Z="1.93820864166889E-14" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="159" WEIGHT="100.0" Z="7.654662316482765">
<NAME>Hypertrichosis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="26.25799171538072" CI_START="1.524935465740388" EFFECT_SIZE="6.32785451996973" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.4192615069674346" LOG_CI_START="0.18325146501665762" LOG_EFFECT_SIZE="0.801256485992046" ORDER="4" O_E="3.5" SE="0.7260384169902695" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="1.8970588235294117" WEIGHT="12.772880203694319"/>
<DICH_DATA CI_END="14.663174840478085" CI_START="3.464866219718297" EFFECT_SIZE="7.127828503730694" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="6" LOG_CI_END="1.166228013035028" LOG_CI_START="0.5396864709363528" LOG_EFFECT_SIZE="0.8529572419856903" ORDER="4" O_E="14.5" SE="0.3680336032594143" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="7.382867132867133" WEIGHT="49.70877880974787"/>
<DICH_DATA CI_END="18.066610367811734" CI_START="3.4331686007819764" EFFECT_SIZE="7.875640890577309" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.2568766784799719" LOG_CI_START="0.5356951318822821" LOG_EFFECT_SIZE="0.896285905181127" ORDER="5" O_E="11.5" SE="0.4236256103777134" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="5.572314049586777" WEIGHT="37.51834098655781"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.391197218631463" CI_START="1.0512793014619144" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.3051551481520307" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="1.0166655875467296" LOG_CI_START="0.02171811371524438" LOG_EFFECT_SIZE="0.519191850630987" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.04080265937697991" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="2.0455297491931415">
<NAME>Headache</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="10.391197218631463" CI_START="1.0512793014619144" EFFECT_SIZE="3.3051551481520307" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="1.0166655875467296" LOG_CI_START="0.02171811371524438" LOG_EFFECT_SIZE="0.519191850630987" ORDER="5" O_E="3.5" SE="0.5844370711980404" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="2.927685950413223" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.021680857250268" CI_END="9.855120607431411" CI_START="2.8367470556720944" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.287389182424955" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="8" I2="50.53620869912565" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.9936619435643639" LOG_CI_START="0.4528206127703691" LOG_EFFECT_SIZE="0.7232412781673665" METHOD="PETO" NO="3" P_CHI2="0.1550678013162472" P_Q="1.0" P_Z="1.5890355891880238E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="5.241932436116596">
<NAME>Tremor</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="8.121451662698776" CI_START="1.2360770539968682" EFFECT_SIZE="3.1683970782410893" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.909633663816512" LOG_CI_START="0.09204554444421387" LOG_EFFECT_SIZE="0.500839604130363" ORDER="4" O_E="5.0" SE="0.4802553084457501" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="4.335664335664336" WEIGHT="43.75932371954252"/>
<DICH_DATA CI_END="18.066610367811734" CI_START="3.4331686007819764" EFFECT_SIZE="7.875640890577309" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="3" LOG_CI_END="1.2568766784799719" LOG_CI_START="0.5356951318822821" LOG_EFFECT_SIZE="0.896285905181127" ORDER="5" O_E="11.5" SE="0.4236256103777134" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="5.572314049586777" WEIGHT="56.240676280457485"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7073926972756474" CI_END="3.591974222352456" CI_START="1.1272651332996686" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0122393745698135" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.5553332113108973" LOG_CI_START="0.05202607433072435" LOG_EFFECT_SIZE="0.3036796428208108" METHOD="PETO" NO="4" P_CHI2="0.7020882259113703" P_Q="1.0" P_Z="0.018022242594089664" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="159" WEIGHT="100.0" Z="2.365160829381301">
<NAME>Dyspepsia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="3.912488991627404" CI_START="1.029098730890457" EFFECT_SIZE="2.0065735610504403" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="22" LOG_CI_END="0.5924531286037831" LOG_CI_START="0.012457042618603429" LOG_EFFECT_SIZE="0.3024550856111933" ORDER="4" O_E="6.0" SE="0.34069257193462343" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="8.615384615384615" WEIGHT="75.30365431130288"/>
<DICH_DATA CI_END="7.540470892577561" CI_START="0.1326177123744814" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8773984678409018" LOG_CI_START="-0.8773984678409018" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="1.0307764064044151" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.9411764705882353" WEIGHT="8.226449630646533"/>
<DICH_DATA CI_END="12.051909988972163" CI_START="0.6932142703618261" EFFECT_SIZE="2.8904248804408916" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0810558794368756" LOG_CI_START="-0.1591325055720779" LOG_EFFECT_SIZE="0.46096168693239886" ORDER="5" O_E="2.0" SE="0.7284927963857741" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="1.884297520661157" WEIGHT="16.469896058050598"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7527100369905203" CI_END="3.814802952458382" CI_START="1.2424839893990403" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.1771154289889476" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.58147211008379" LOG_CI_START="0.09429080113941507" LOG_EFFECT_SIZE="0.3378814556116026" METHOD="PETO" NO="5" P_CHI2="0.686358772576716" P_Q="1.0" P_Z="0.0065550756581278175" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="159" WEIGHT="100.0" Z="2.718640768372837">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="11.57677531189491" CI_START="0.8291450538521326" EFFECT_SIZE="3.0981972160298548" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0635876043585952" LOG_CI_START="-0.08136948564170636" LOG_EFFECT_SIZE="0.49110905935844446" ORDER="4" O_E="2.5" SE="0.672553462295179" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.2107843137254903" WEIGHT="18.105178643115217"/>
<DICH_DATA CI_END="4.719836205852313" CI_START="1.103211976026521" EFFECT_SIZE="2.2818807653293036" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="14" LOG_CI_END="0.6739269274203581" LOG_CI_START="0.04265896772000735" LOG_EFFECT_SIZE="0.35829294757018276" ORDER="4" O_E="6.0" SE="0.3708099243547831" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="7.272727272727273" WEIGHT="59.559870077734395"/>
<DICH_DATA CI_END="4.727912612829347" CI_START="0.4403653905169176" EFFECT_SIZE="1.442916866655337" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6746694407757503" LOG_CI_START="-0.35618682071336555" LOG_EFFECT_SIZE="0.15924131003119232" ORDER="5" O_E="1.0" SE="0.6055300708194983" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="2.7272727272727275" WEIGHT="22.3349512791504"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6153406729138846" CI_END="4.881103706646979" CI_START="1.117815291097951" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.335845106321239" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.6885180350169088" LOG_CI_START="0.04837004623000316" LOG_EFFECT_SIZE="0.368444040623456" METHOD="PETO" NO="6" P_CHI2="0.7351576723183258" P_Q="1.0" P_Z="0.0240608264591977" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="159" TOTAL_2="159" WEIGHT="100.0" Z="2.2561565843824702">
<NAME>Paraesthesia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="11.57677531189491" CI_START="0.8291450538521326" EFFECT_SIZE="3.0981972160298548" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="1.0635876043585952" LOG_CI_START="-0.08136948564170636" LOG_EFFECT_SIZE="0.49110905935844446" ORDER="4" O_E="2.5" SE="0.672553462295179" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="2.2107843137254903" WEIGHT="31.259523182146257"/>
<DICH_DATA CI_END="5.153691975993691" CI_START="0.5314852896708578" EFFECT_SIZE="1.655026124487279" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.712118458234326" LOG_CI_START="-0.2745087512783776" LOG_EFFECT_SIZE="0.21880485347797415" ORDER="4" O_E="1.5" SE="0.5795497067512154" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="2.9772727272727275" WEIGHT="42.09733408182204"/>
<DICH_DATA CI_END="12.051909988972163" CI_START="0.6932142703618261" EFFECT_SIZE="2.8904248804408916" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0810558794368756" LOG_CI_START="-0.1591325055720779" LOG_EFFECT_SIZE="0.46096168693239886" ORDER="5" O_E="2.0" SE="0.7284927963857741" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="1.884297520661157" WEIGHT="26.64314273603171"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.892941843424183" CI_START="0.5282211126339814" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.0418664311087613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.8972389028594624" LOG_CI_START="-0.27718424433092587" LOG_EFFECT_SIZE="0.31002732926426824" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.3007656283145369" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="61" WEIGHT="99.99999999999999" Z="1.034792955221957">
<NAME>Flushing</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="7.892941843424183" CI_START="0.5282211126339814" EFFECT_SIZE="2.0418664311087613" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8972389028594624" LOG_CI_START="-0.27718424433092587" LOG_EFFECT_SIZE="0.31002732926426824" ORDER="5" O_E="1.5" SE="0.6898619701479713" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="2.1012396694214877" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04277253282549349" CI_END="3.0841065016116334" CI_START="0.5673997246139376" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.322845863921604" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.4891293668703663" LOG_CI_START="-0.2461108793238752" LOG_EFFECT_SIZE="0.1215092437732455" METHOD="PETO" NO="8" P_CHI2="0.836154294761063" P_Q="1.0" P_Z="0.5170977336958194" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="0.6478256401686198">
<NAME>Diarrhea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="3.309727991473677" CI_START="0.5597498913007198" EFFECT_SIZE="1.3611097984594558" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.5197923029430346" LOG_CI_START="-0.2520059820856934" LOG_EFFECT_SIZE="0.13389316042867055" ORDER="4" O_E="1.5" SE="0.45335813308900136" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="4.865384615384615" WEIGHT="90.75089674799158"/>
<DICH_DATA CI_END="16.172833435163252" CI_START="0.06183208427941778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2087861137503029" LOG_CI_START="-1.2087861137503029" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="1.420093893609386" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" VAR="0.49586776859504134" WEIGHT="9.24910325200842"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.044520703462215E-5" CI_END="30.162266802778422" CI_START="2.10524205493015" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.9686179821367205" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="1.4794639772157887" LOG_CI_START="0.3233020370253054" LOG_EFFECT_SIZE="0.9013830071205471" METHOD="PETO" NO="9" P_CHI2="0.9949257639626516" P_Q="1.0" P_Z="0.0022423001555355276" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="98" WEIGHT="100.00000000000001" Z="3.0561086104280766">
<NAME>Gum hyperplasia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="80.68311939294827" CI_START="0.7967103672137344" EFFECT_SIZE="8.017548108961082" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9067826806780037" LOG_CI_START="-0.09869953152977168" LOG_EFFECT_SIZE="0.904041574574116" ORDER="4" O_E="1.5" SE="1.178030178747903" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.7205882352941176" WEIGHT="33.23530806811175"/>
<DICH_DATA CI_END="40.508050218850386" CI_START="1.5580371799126762" EFFECT_SIZE="7.944372116582829" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.6075413397135079" LOG_CI_START="0.19257781716084002" LOG_EFFECT_SIZE="0.900059578437174" ORDER="4" O_E="3.0" SE="0.8311565773298358" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" VAR="1.4475524475524477" WEIGHT="66.76469193188827"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" METHOD="PETO" NO="10" P_CHI2="1.0" P_Q="1.0" P_Z="0.31731052126128756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.0">
<NAME>Gastric ulceration</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4" O_E="0.5" SE="2.0" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.25" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="372.3848896839504" CI_START="0.1466175227450357" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" METHOD="PETO" NO="11" P_CHI2="1.0" P_Q="1.0" P_Z="0.31731052126128756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.0">
<NAME>Mammary hypertrophy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="372.3848896839504" CI_START="0.1466175227450357" EFFECT_SIZE="7.38905609893065" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.570992050236215" LOG_CI_START="-0.8338141226232083" LOG_EFFECT_SIZE="0.8685889638065036" ORDER="4" O_E="0.5" SE="2.0" STUDY_ID="STD-Dougados-1988" TOTAL_1="26" TOTAL_2="26" VAR="0.25" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Cyclosporine vs placebo - Efficacy-12 months</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3.7569988558041523" CI_START="-12.64300114419585" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.200000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="2.976827152288865E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="99.99999999999999" Z="3.617308245401613">
<NAME>Change in number of tender joints</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.7569988558041523" CI_START="-12.64300114419585" EFFECT_SIZE="-8.200000000000001" ESTIMABLE="YES" MEAN_1="-9.4" MEAN_2="-1.2" ORDER="4" SD_1="14.42" SD_2="12.73" SE="2.266878972900357" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.909140868304222" CI_END="-2.0950776319886937" CI_START="-4.28660774920194" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.190842690595317" ESTIMABLE="YES" I2="31.251180656444895" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.23350069544800112" P_Q="1.0" P_Z="1.1473510955736585E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="5.707370119879732">
<NAME>Change in number of swollen joints</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.49312502846662576" CI_START="-4.106874971533375" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="-3.2" MEAN_2="-0.9" ORDER="4" SD_1="5.94" SD_2="5.09" SE="0.9218919254566786" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="36.77720249702834"/>
<CONT_DATA CI_END="-2.2879164701211634" CI_START="-8.592083529878835" EFFECT_SIZE="-5.4399999999999995" ESTIMABLE="YES" MEAN_1="-3.36" MEAN_2="2.08" ORDER="4" SD_1="4.63" SD_2="6.22" SE="1.6082354342947465" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="12.084799792785079"/>
<CONT_DATA CI_END="-1.76769369708827" CI_START="-4.83230630291173" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="-3.6" MEAN_2="-0.3" ORDER="5" SD_1="4.69" SD_2="3.91" SE="0.7818032958760298" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="51.137997710186575"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="35.6222095777116" CI_END="0.4108129724878236" CI_START="-0.24993130719659212" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08044083264561575" ESTIMABLE="YES" I2="97.19276257184875" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="2.395479148376012E-9" P_Q="1.0" P_Z="0.6332034416340514" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="0.4772228522269545">
<NAME>Change in patient overall assessment</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3609785187842687" CI_START="-1.239021481215731" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.9" ORDER="4" SD_1="0.85" SD_2="1.7" SE="0.22399466759526018" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="56.62853041154603"/>
<CONT_DATA CI_END="1.7316506130728084" CI_START="0.7283493869271915" EFFECT_SIZE="1.23" ESTIMABLE="YES" MEAN_1="2.02" MEAN_2="0.79" ORDER="5" SD_1="1.56" SD_2="1.25" SE="0.2559488934642496" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="43.37146958845397"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="27.17321124075243" CI_END="0.6909716866992319" CI_START="-0.018674797643256413" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.33614844452798776" ESTIMABLE="YES" I2="96.31990495661303" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="1.8602067652917498E-7" P_Q="1.0" P_Z="0.0633383908768283" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" UNITS="" WEIGHT="100.0" Z="1.8568085920821633">
<NAME>Change in physician overall assessment</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.24467687104698443" CI_START="-1.3553231289530152" EFFECT_SIZE="-0.7999999999999998" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="2.9" ORDER="4" SD_1="1.7" SD_2="1.7" SE="0.2833333333333333" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="40.82560184750064"/>
<CONT_DATA CI_END="1.5812592995324493" CI_START="0.658740700467551" EFFECT_SIZE="1.12" ESTIMABLE="YES" MEAN_1="1.79" MEAN_2="0.67" ORDER="5" SD_1="1.48" SD_2="1.09" SE="0.2353407017530953" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="59.17439815249936"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.1211252130548974" CI_END="4.4270946591230995" CI_START="-5.494975093794922" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5339402173359109" ESTIMABLE="YES" I2="3.880818768444807" I2_Q="3.7515995629412227" ID="CMP-003.05" NO="5" P_CHI2="0.37332473775090425" P_Q="0.3080595421507635" P_Z="0.8329304891330056" Q="1.0389783055708501" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="216" TOTAL_2="218" UNITS="" WEIGHT="200.00000000000003" Z="0.2109446157779941">
<NAME>Acute phase reactants</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.0821469074840473" CI_END="4.851142999653867" CI_START="-5.173852219109966" DF="2" EFFECT_SIZE="-0.1613546097280496" ESTIMABLE="YES" I2="3.945298345125375" ID="CMP-003.05.01" NO="1" P_CHI2="0.35307562886736665" P_Z="0.9496931295655017" STUDIES="3" TAU2="0.0" TOTAL_1="155" TOTAL_2="157" WEIGHT="100.00000000000003" Z="0.06309214456572872">
<NAME>Change in ESR</NAME>
<CONT_DATA CI_END="7.783599525433155" CI_START="-4.183599525433156" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="-1.6" MEAN_2="-3.4" ORDER="4" SD_1="13.58" SD_2="22.06" SE="3.052912998723969" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="70.1751450328505"/>
<CONT_DATA CI_END="10.47058727395605" CI_START="-13.47058727395605" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.0" ORDER="5" SD_1="36.71" SD_2="30.46" SE="6.107554714463386" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="17.53385627768895"/>
<CONT_DATA CI_END="4.847516035864066" CI_START="-23.747516035864066" EFFECT_SIZE="-9.45" ESTIMABLE="YES" MEAN_1="-8.91" MEAN_2="0.54" ORDER="17102" SD_1="28.42" SD_2="19.9" SE="7.294785082093878" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="12.290998689460572"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="16.310073439219643" CI_START="-53.11007343921964" DF="0" EFFECT_SIZE="-18.4" ESTIMABLE="YES" I2="0.0" ID="CMP-003.05.02" NO="2" P_CHI2="1.0" P_Z="0.29881049913751345" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="1.0389876408267196">
<NAME>Change in CRP</NAME>
<CONT_DATA CI_END="16.310073439219643" CI_START="-53.11007343921964" EFFECT_SIZE="-18.4" ESTIMABLE="YES" MEAN_1="-13.4" MEAN_2="5.0" ORDER="5" SD_1="62.48" SD_2="123.4" SE="17.709546559532864" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.885364806866952" CI_END="-0.07110849698678579" CI_START="-0.3185567390647164" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19483261802575108" ESTIMABLE="YES" I2="65.34233738416457" I2_Q="65.34233738416457" ID="CMP-003.06" NO="6" P_CHI2="0.08938789064591635" P_Q="0.08938789064591635" P_Z="0.002025807292920286" Q="2.885364806866952" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="74" TOTAL_2="46" UNITS="" WEIGHT="200.0" Z="3.08642252729246">
<NAME>Radiologic evaluation</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.055097774153034754" CI_START="-0.3049022258469653" DF="0" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.01" NO="1" P_CHI2="1.0" P_Z="0.004734595411875898" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0" Z="2.8245574874659574">
<NAME>Change in larsen score</NAME>
<CONT_DATA CI_END="-0.055097774153034754" CI_START="-0.3049022258469653" EFFECT_SIZE="-0.18000000000000002" ESTIMABLE="YES" MEAN_1="-0.01" MEAN_2="0.17" ORDER="5" SD_1="0.24" SD_2="0.24" SE="0.06372679642696401" STUDY_ID="STD-Forre-1994" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0670597424933671" CI_START="-1.8729402575066327" DF="0" EFFECT_SIZE="-0.97" ESTIMABLE="YES" I2="0.0" ID="CMP-003.06.02" NO="2" P_CHI2="1.0" P_Z="0.03524546214153546" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0" Z="2.1055269705813147">
<NAME>Change in erosion score</NAME>
<CONT_DATA CI_END="-0.0670597424933671" CI_START="-1.8729402575066327" EFFECT_SIZE="-0.97" ESTIMABLE="YES" MEAN_1="0.06" MEAN_2="1.03" ORDER="5" SD_1="1.82" SD_2="1.68" SE="0.4606922701788963" STUDY_ID="STD-Forre-1994" TOTAL_1="37" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.19032068806418892" CI_END="-2.328649989108184" CI_START="-5.158645770133627" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7436478796209056" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.909227193710328" P_Q="0.8305240018806977" P_Z="2.154822907117552E-7" Q="0.045808738959297685" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="200.0" Z="5.185460037822401">
<NAME>Index scores</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.14451194910489124" CI_END="-2.3271831451407166" CI_START="-5.157296428275375" DF="1" EFFECT_SIZE="-3.7422397867080455" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.01" NO="1" P_CHI2="0.7038362283385685" P_Z="2.1800048802319916E-7" STUDIES="2" TAU2="0.0" TOTAL_1="83" TOTAL_2="85" WEIGHT="100.0" Z="5.183294426530302">
<NAME>Change in Lee functional index</NAME>
<CONT_DATA CI_END="-1.38296786900349" CI_START="-5.51703213099651" EFFECT_SIZE="-3.45" ESTIMABLE="YES" MEAN_1="-3.91" MEAN_2="-0.46" ORDER="4" SD_1="3.01" SD_2="4.1" SE="1.0546276091300635" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="46.86549332580997"/>
<CONT_DATA CI_END="-2.0587319909685964" CI_START="-5.941268009031404" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="-2.2" MEAN_2="1.8" ORDER="5" SD_1="5.47" SD_2="5.47" SE="0.9904610617051527" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="53.13450667419003"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="134.5831674168705" CI_START="-175.9831674168705" DF="0" EFFECT_SIZE="-20.7" ESTIMABLE="YES" I2="0.0" ID="CMP-003.07.03" NO="3" P_CHI2="1.0" P_Z="0.7938822078403558" STUDIES="1" TAU2="0.0" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="0.2612727132945597">
<NAME>Change in problem elicitation technique (PET)</NAME>
<CONT_DATA CI_END="134.5831674168705" CI_START="-175.9831674168705" EFFECT_SIZE="-20.7" ESTIMABLE="YES" MEAN_1="-44.9" MEAN_2="-24.2" ORDER="4" SD_1="450.57" SD_2="498.93" SE="79.22756164997128" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1018941681471146" CI_END="-18.250639964245032" CI_START="-90.37489023494652" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-54.31276509959578" ESTIMABLE="YES" I2="4.847730665570927" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="0.3496066604565822" P_Q="1.0" P_Z="0.0031584571913137794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.00000000000001" Z="2.9518799321019658">
<NAME>Change in duration of morning stiffness</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="19.810976840282066" CI_START="-163.81097684028208" EFFECT_SIZE="-72.0" ESTIMABLE="YES" MEAN_1="-102.0" MEAN_2="-30.0" ORDER="4" SD_1="254.4" SD_2="305.4" SE="46.843195877309654" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="15.42813447946983"/>
<CONT_DATA CI_END="-21.452892779303923" CI_START="-171.30710722069608" EFFECT_SIZE="-96.38" ESTIMABLE="YES" MEAN_1="-108.05" MEAN_2="-11.67" ORDER="4" SD_1="112.22" SD_2="146.07" SE="38.22881839243554" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="23.164594417116458"/>
<CONT_DATA CI_END="12.019449269533887" CI_START="-80.01944926953388" EFFECT_SIZE="-34.0" ESTIMABLE="YES" MEAN_1="-46.2" MEAN_2="-12.2" ORDER="5" SD_1="131.99" SD_2="127.31" SE="23.479742297577623" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="61.40727110341372"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5638450782421647" CI_END="27.596219982424888" CI_START="5.188038092267053" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="16.39212903734597" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.09" NO="9" P_CHI2="0.45752570379421276" P_Q="1.0" P_Z="0.004136994259639956" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="100.00000000000001" Z="2.8675224701958215">
<NAME>Change in Grip Strength</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="40.916078209697325" CI_START="-11.316078209697324" EFFECT_SIZE="14.8" ESTIMABLE="YES" MEAN_1="16.68" MEAN_2="1.88" ORDER="4" SD_1="48.29" SD_2="41.44" SE="13.324774544684297" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="18.405063906563285"/>
<CONT_DATA CI_END="33.90633876801876" CI_START="6.693661231981238" EFFECT_SIZE="20.3" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="1.8" ORDER="4" SD_1="44.12" SD_2="39.03" SE="6.942137138918789" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="67.80640062775554"/>
<CONT_DATA CI_END="29.472934857669365" CI_START="-30.872934857669364" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="6.6" MEAN_2="7.3" ORDER="5" SD_1="111.69" SD_2="44.52" SE="15.394637399293876" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="13.788535465681198"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.095562758606433" CI_END="-2.440970815211618" CI_START="-9.889292275154059" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.165131545182838" ESTIMABLE="YES" I2="8.722709662748096" I2_Q="0.0" ID="CMP-003.10" NO="10" P_CHI2="0.295242441847977" P_Q="1.0" P_Z="0.001176130632884556" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="3.2446064132692567">
<NAME>Change in PIP circumference</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.1924454971885403" CI_START="-16.92755450281146" EFFECT_SIZE="-9.56" ESTIMABLE="YES" MEAN_1="-3.77" MEAN_2="5.79" ORDER="4" SD_1="11.75" SD_2="13.73" SE="3.759025451960235" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="25.55113037681663"/>
<CONT_DATA CI_END="-0.6838218462454231" CI_START="-9.316178153754578" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-5.0" MEAN_2="0.0" ORDER="17118" SD_1="10.93" SD_2="13.28" SE="2.202172176529793" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="74.44886962318337"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.018429237770830897" CI_END="-2.017447699111642" CI_START="-8.195116887311473" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.1062822932115575" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.11" NO="11" P_CHI2="0.8920155035142348" P_Q="1.0" P_Z="0.0011948827249374132" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="83" TOTAL_2="85" UNITS="" WEIGHT="100.0" Z="3.240098841390247">
<NAME>Change in Ritchie Joint Score</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.26802536322654635" CI_START="-9.471974636773453" EFFECT_SIZE="-4.87" ESTIMABLE="YES" MEAN_1="-4.91" MEAN_2="-0.04" ORDER="4" SD_1="7.81" SD_2="8.11" SE="2.3479893881077625" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="45.050629485684325"/>
<CONT_DATA CI_END="-1.1330979495085156" CI_START="-9.466902050491486" EFFECT_SIZE="-5.300000000000001" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-2.4" ORDER="5" SD_1="12.5" SD_2="10.93" SE="2.1260094998476893" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="54.94937051431568"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="15.636662281322096" CI_END="0.49502690988384934" CI_START="-0.03267722978814114" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.2311748400478541" ESTIMABLE="YES" I2="87.20954661539893" I2_Q="93.59776600319196" ID="CMP-003.12" NO="12" P_CHI2="4.022937486547473E-4" P_Q="7.745039486461991E-5" P_Z="0.0859373840942885" Q="15.619547809382968" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="155" TOTAL_2="157" UNITS="" WEIGHT="200.0" Z="1.7172287521080867">
<NAME>Pain scores</NAME>
<GROUP_LABEL_1/>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.017114471939126966" CI_END="-0.5731549980090026" CI_START="-2.317901123737127" DF="1" EFFECT_SIZE="-1.445528060873065" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.01" NO="1" P_CHI2="0.8959158934704388" P_Z="0.0011635267406464157" STUDIES="2" TAU2="0.0" TOTAL_1="94" TOTAL_2="96" WEIGHT="100.0" Z="3.247673568291633">
<NAME>Change in pain (10 cm VAS)</NAME>
<CONT_DATA CI_END="-0.10370639769457801" CI_START="-2.936293602305422" EFFECT_SIZE="-1.52" ESTIMABLE="YES" MEAN_1="-1.84" MEAN_2="-0.32" ORDER="4" SD_1="2.77" SD_2="2.04" SE="0.7226120548525203" STUDY_ID="STD-Dougados-1988" TOTAL_1="22" TOTAL_2="24" WEIGHT="37.94005072755414"/>
<CONT_DATA CI_END="-0.2926203487348691" CI_START="-2.507379651265131" EFFECT_SIZE="-1.4" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-0.9" ORDER="5" SD_1="3.39" SD_2="3.39" SE="0.5650000000000001" STUDY_ID="STD-Tugwell-1990" TOTAL_1="72" TOTAL_2="72" WEIGHT="62.059949272445856"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.6768170104286098" CI_START="0.12318298957139034" DF="0" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" ID="CMP-003.12.02" NO="2" P_CHI2="1.0" P_Z="0.004623704242544799" STUDIES="1" TAU2="0.0" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0" Z="2.8321438505608363">
<NAME>Change in pain (1-max pain to 4-no pain, Likert scale)</NAME>
<CONT_DATA CI_END="0.6768170104286098" CI_START="0.12318298957139034" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.1" ORDER="4" SD_1="0.78" SD_2="0.78" SE="0.1412357638263289" STUDY_ID="STD-Forre-1994" TOTAL_1="61" TOTAL_2="61" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>